Form 4: Ionis Pharma EVP Baroldi Exercises Options, Sells Shares

Ionis Pharmaceuticals' EVP, Chief Business Officer Joseph Baroldi, exercised stock options and subsequently sold 11,950 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Joseph Baroldi, EVP, Chief Business Officer of Ionis Pharmaceuticals Inc. (IONS), exercised non-qualified stock options to acquire 11,950 shares of common stock at an exercise price of $31.80 per share.
• Concurrently, Mr. Baroldi sold 11,950 shares of common stock at a weighted average price of $62.1622 per share.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on May 2, 2025.
• The shares were sold in multiple transactions with prices ranging from $62.00 to $62.44.
• Following these transactions, Mr. Baroldi directly holds 31,926 shares of common stock and indirectly holds 3,071 shares through his spouse.
• He also retains 41,700 non-qualified stock options.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine insider sale under a 10b5-1 plan, indicating a planned monetization of vested equity rather than a reaction to new information. While an insider sale can be seen as slightly negative, the pre-arranged nature mitigates this, making it largely neutral.

Positives

• The exercise of options indicates a profit for the executive, as the sale price ($62.1622) was significantly higher than the exercise price ($31.80).
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned, rather than opportunistic, sale.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be interpreted by the market as a signal that the executive believes the stock price may not rise significantly in the near term.

Future Outlook

NA

Industry Context

Insider transactions, particularly sales, are common in the biotechnology and pharmaceutical sectors as executives monetize vested equity. The use of a 10b5-1 plan is standard practice to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: The sale of shares by an executive could be perceived as a slight negative signal, though mitigated by the 10b5-1 plan. It represents a small increase in the float.
• Management: Joseph Baroldi has monetized a portion of his equity compensation.

Key Dates

Recommendation

The filing details a routine insider transaction where an executive exercised options and sold shares under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of new material information about the company's prospects, either positive or negative. Therefore, it does not provide a basis for changing an existing investment thesis, leading to a 'hold' recommendation based solely on this filing.

Keywords

Ionis Pharmaceuticals, IONS, Joseph Baroldi, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Executive Compensation, Biotechnology